Clinical Trial

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
patients with MDS (Myelodysplastic Syndrome) and mutated IDH1 patients will be treated with AG120 (IDH1 inhibitor)
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2018-04-11; most recent amendment 2025-05-16.
Status change: Recruiting → Active, Not Recruiting 2024-04-18
Status change: Not Yet Recruiting → Recruiting 2019-03-26
Trial Details
NCT Number NCT03503409
Lead Sponsor Groupe Francophone des Myelodysplasies
Conditions Myelodysplastic Syndromes, Acute Myeloid Leukemia
Enrollment 68 participants
Start Date 2019-05-14
Primary Completion 2027-04-02 (estimated)
Study Completion 2027-04-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-10